Experimental models using patient-derived liver spheroids have demonstrated heightened steatosis and fibrogenesis in PNPLA3 GG carriers, with differential responses to emerging therapies such as resmetirom, a thyroid hormone receptor-β agonist [35]. This evidence concerns the gene PNPLA3 and steatosis.